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Statin drugs are a class of drug that work to reduce endogenous production of 
cholesterol by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(Hmgcr) thus inhibiting production of mevalonic acid in the mevalonate pathway.  
Atorvastatin (Lipitor) is one of the most widely prescribed statin drugs and contamination 
of wastewater effluent is a growing environmental concern because of the potential to 
interfere with steroidogenesis in wildlife. Amphibians may be particularly susceptible to 
the effects of atorvastatin contamination because of their highly permeable integument.  I 
used an amphibian model, Xenopus laevis to test the hypothesis that chronic exposure to 
low concentrations of atorvastatin in water has an adverse effect on steroid hormone 
levels, growth and development.  This hypothesis was tested via a series of toxicity 
assays designed to evaluate potential endocrine disrupting effects of atorvastatin using 
traditional aquatic toxicology assays combined with modern molecular biology 
techniques to identify and report regulatory alteration of physiological pathways.  Results 
indicated significant dose-dependent upregulation of steroidogenesis as confirmed by 
both qPCR and total RNA sequencing and supported by evidence of alteration of 
testosterone and estradiol concentrations.  Such effects have the potential to significantly 
alter sex ratios in amphibian populations localized around wastewater effluent sites.  This 
research provides insight into the potentially harmful effects of relatively low 
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CHAPTER I – INTRODUCTION AND BACKGROUND 
Statin drugs are a class of drug that work to reduce endogenous production of 
cholesterol by competitively inhibiting 3-hydroxy-3-methyl-glutaryl-CoA reductase 
(Hmgcr) thus inhibiting production of mevalonic acid in the mevalonate pathway.  This 
results in reduced cholesterol biosynthesis in humans and helps to reduce high cholesterol 
levels (hypercholesterolemia) and the risk of cardiovascular disease.   
Atorvastatin (Lipitor) as one of the most widely prescribed statin drugs (Stagnitti, 
2007).  Since new statin drugs are created constantly, prescription rates and use have 
likely declined, however atorvastatin remains one of the most highly prescribed 
medications in the western world.  A recent study of patients in the US Department of 
Veteran Affairs found that 79% of all patients at their facilities were prescribed a statin of 
some type (McBride et al., 2018).  In the US, it is estimated that 27.8% of the population 
40 years and older take statin medications, and the medical community widely considers 
these rates to be considerably lower than target rates for a healthy population (Salami et 
al., 2017).  This is primarily due to the high rate of hypercholesterolemia in developed 
countries for which atorvastatin is designed to treat by reducing endogenous production 
of cholesterol.   
1.1 Wastewater Effluent. 
It has been suggested for quite some time that pharmaceutical contamination of 
wastewater effluent is a growing environmental concern.  Numerous studies report active 
pharmaceutical compounds detected in both wastewater effluent and surface waters (Batt, 
Kostich, & Lazorchak, 2008; Chen et al., 2006; Ort et al., 2010; Richards & Cole, 2006).  
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The sources of these compounds vary from hospital input to improper disposal of expired 
medications and residential sewage and agricultural runoff. 
Modern engineering solutions to effectively remove pharmaceutical contaminants 
from wastewater effluent are either too costly or impractical, and as a result, 
pharmaceuticals continue to be discharged in wastewater effluent at increasing rates 
(Halling-Sorensen et al., 1998).  While designs of wastewater treatment plants vary from 
activated sludge digestion to spray field irrigation, almost all wastewater treatment 
methodologies involve mechanical, photochemical, and biological filtration.  Photo 
degradation accounts for some removal of pharmaceuticals, but it is not significant 
enough to reduce pharmaceutical levels below detectable levels.  A recent study of 3 
conventional wastewater treatment plants in Spain over a 2-year period showed removal 
rates of ~50%, with atorvastatin effluent concentrations in the 2 ng L-1 range (Jelic et al., 
2011).  Moreover, accumulation in lakes and streams in locations near effluent sites is not 
uncommon.   
Concentrations of atorvastatin ranging from 1-4 μg L-1 have been detected in 
waters adjacent to effluent sites in Canada (Lee, Peart, Svoboda, & Backus, 2009).  As 
these chronic low levels of atorvastatin are continuously discharged into the surrounding 
ecosystem, small aquatic organisms such as fish and amphibians are exposed, and 
potentially affected by atorvastatin.  Little is known about environmental degradation of 
atorvastatin.  A 2005 study of photodegradation of atorvastatin suggested an 
environmental half-life of 0.6 – 2.4 hours in surface water and noted that 
photodegradation is enhanced in the presence of dissolved organic matter(Lam & 
Mabury, 2005).  While this short half-life is favorable to the environment, high influent 
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rates of atorvastatin to wastewater treatment plants allow for replacement of degraded 
atorvastatin resulting the localized concentrations near wastewater effluent sites. 
1.2 Endogenous Production of Cholesterol. 
In humans, LDL/HDL cholesterol ratios are inflated in large part, due to 
endogenous production of cholesterol (Kapourchali, Surendiran, Goulet, & Moghadasian, 
2016).  Hypercholesterolemia is caused by high levels of LDL cholesterol proportional to 
HDL cholesterol in the body (Kapourchali et al., 2016).   
Endogenous cholesterol production occurs across 3 primary pathways.  These 
pathways are fatty acid metabolism, the mevalonate, or isoprenoid, pathway, and the 





Figure 1.1 Cholesterol biosynthesis and regulation of the mevalonate pathway 
(Gruenbacher & Thurnher, 2017). 
The fatty acid metabolism pathway converts carbohydrates via glycolysis, and lipids via 
β-oxidation into acetyl coenzyme A (Acetyl-CoA).  Next, the mevalonate pathway 
converts Acetyl-CoA into isopentenyl pyrophosphate (IPP) and dimethylallyl 
pyrophosphate (DMAPP). IPP and DMAPP are then used in the squalene synthesis 
pathway for conversion into cholesterol.   
 In this general overview of endogenous cholesterol production, the mevalonate 
pathway can be considered the rate limiting step in conversion of fatty acids to 
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cholesterol.  For animals with potentially low input of dietary cholesterol, this could 
reduce cholesterol levels significantly because endogenous production of cholesterol 
accounts for two thirds of all cholesterol in the body (Kapourchali et al., 2016).  
Atorvastatin blocks endogenous production of cholesterol by competitively inhibiting the 
active site of Hmgcr.  This effectively blocks conversion of fatty acids to cholesterol and 
reduces the LDL/HDL ratio as treatment for hypercholesterolemia.  An animal exposed 
to atorvastatin could experience hypocholesterolemia due to the reduced ability of the 
body to effectively regulate endogenous production of cholesterol to compensate for 
decreased dietary input such as in amphibians.   
In amphibians, dietary cholesterol input has a far less significant contribution to 
overall cholesterol level than in the human model (Hadfield, Clayton, & Barnett, 2006).  
This is because amphibians, and frogs in particular, tend to rely on diets based heavily on 
plant matter and insects that contribute little to endogenous cholesterol levels(Hadfield et 
al., 2006).  This natural high protein/low fat diet combined with naturally low body fat 
reserves suggests that shutting down endogenous cholesterol production via exposure to 
statin drugs could adversely affect frogs in ways not evident in humans. 
1.3 Pharmacology and Pharmacodynamics of Atorvastatin. 
Atorvastatin was developed to combat the hypercholesterolemia epidemic that 
currently plagues modern societies.  Hypercholesterolemia, and by extension 
atherosclerosis and coronary heart disease are one of the leading causes of death in 
developed countries.  Indeed, among the US population, heart disease is the leading cause 
of death, and has held this top spot for quite some time (CDC, 2019).  This study shows 
that between 1999 and 2017 over 12 million deaths in the US were associated with 
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diseases primarily treatable by statin drugs.  Atorvastatin, and statin drugs in general, 
work to reduce endogenous production of cholesterol and, in turn, reduce mean total 
cholesterol in the body.  The prescribed dosage range in humans of atorvastatin is 10-80 
mg/day (Lennernäs, 2003).  Since the mass of an average human is approximately 80 kg, 
mathematically, this resolves to be a concentration of 0.125-1 mg kg-1 of body mass.  At 
this dosage, smaller aquatic species undergoing chronic exposure have the potential to 
reach circulating atorvastatin concentrations in the range of efficacy for atorvastatin. 
In humans, atorvastatin is administered orally as a tablet in the calcium salt form 
of the hydroxyl acid.  Metabolism and uptake of atorvastatin occurs primarily in the gut.  
At the physiologically relevant pH of 6, the solubility of the acid form is high, and as a 
result, uptake into the intestinal lumen is high.  The uptake mechanism of atorvastatin 
calcium is complex and not well understood.  Atorvastatin is administered in its active 
form, and given its high lipophilicity (logKo/w = 6.36) (National Center for Biotechnology 
Information, n.d.), absorption across the gut wall is assumed to be rapid with the bulk of 
the uptake driven primarily by passive diffusion across the intestinal lumen and into the 
enterocyte.  Following uptake, atorvastatin serves as a substrate for Cyp3a4 in the 
intestinal lumen.  The protein encoded by cyp3a4 metabolizes a wide range of 
pharmaceuticals and is useful as a biomarker indicating uptake and metabolism of 
atorvastatin.  When atorvastatin is administered, the acid undergoes glucuronidation and 
is converted to its lactone form.  The lactone has a much higher affinity for the Cyp3a4 
protein, and conversion from the active acid form to the inactive lactone form in the liver 
is considered to be the primary route of elimination (Jacobsen et al., 2000).  The Cyp3a4 
protein converts both the lactone and acid forms into their oxidized and μ-oxidized forms, 
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respectively.  With respect to the acid forms, Cyp3a4 converts the open acid to 2-hydroxy 
atorvastatin acid and 4-hydroxy atorvastatin acid.  Of the two, 2-hydroxy atorvastatin 
acid is the dominant acid metabolite (Jacobsen et al., 2000).  Figure 1.2 shows a 
hypothetical metabolic pathway for atorvastatin (Lennernäs, 2003). 
 
Figure 1.2 Hypothetical representation of the metabolic pathways associated with 
CYP3A4 metabolism of atorvastatin (Lennernäs, 2003). 
Once inside the human body, it has a low bioavailability of 14% with serum 
concentrations reaching tmax within 1.5 hours of the initial dose (Gibson, Stern, Abel, & 
Whitfield, 1997).  This high uptake and low bioavailability of atorvastatin allow 
comparatively high levels of the active compound to be excreted from the body via urine 
and feces.  Repeated dose studies show that steady state is achieved within the first 72 
hours, increases proportional to dose, and the remaining 70-80% of the dose is excreted 
as the parent compound within 11 to 14 days (Black et al., 1999; Cilla Jr., Whitfield, 
Gibson, Sedman, & Posvar, 1996).   
 
8 
Once metabolized and inside the body, atorvastatin works as a competitive 
inhibitor of Hmgcr.  This competitive inhibition leads to decreased mevalonate levels, 
and consequently, reduced endogenous production of cholesterol.  As mevalonate levels 
drop, upregulation of the genes encoding for Hmcgr are seen.  This is one of several 
feedback loops regulating mevalonate production and makes the hmgcr gene a useful 
biomarker indicating exposure to atorvastatin.  Multiple studies show evidence of dose 
dependent reductions in LDL-cholesterol as well as reductions in mean total cholesterol 
following administration of statin drugs in humans.  (Cilla Jr. et al., 1996; Nawrocki et 
al., 1995). 
In general, statin drugs show a wide variety of beneficial effects in humans.  
These beneficial effects include reduction in inflammation and reduced cholesterol 
plaque build-up in arterial walls (Lennernäs, 2003).  These beneficial effects come with 
relatively few harmful side effects in humans, however, little work has been done to 
assess potential harmful side effects to atorvastatin exposure and associated cholesterol 
reduction in non-target species such as amphibians. 
1.4 Steroidogenesis. 
If exposure to environmental statins reduces circulating cholesterol levels in 
amphibians, it is possible that this reduction affects circulating hormone levels as well.  
In broad terms, cholesterol serves as a precursor molecule for steroidogenesis, following 
a well-described pathway (Figure 1.3).  This pathway is responsible for conversion of 
cholesterol to the sex steroids estradiol and testosterone, in addition to production of the 
stress hormone cortisol.  It is the close connection between cholesterol and sex steroid 




Figure 1.3 The steroidogenesis pathway (Miller, 2018). 
The rate-limiting step in steroidogenesis is conversion of cholesterol to 
pregnenolone via enzymatic reaction with cholesterol side-chain cleavage enzyme 
(P450scc).  This reaction is mediated by Steroidogenic Acute Regulatory protein (Star), 
which functions to move cholesterol from the outer mitochondrial membrane to the inner 
mitochondrial membrane where the P450scc reaction takes place.  Since Star is believed 
to be constitutively expressed, and cholesterol availability is unlikely to be an issue, it is 
the rate at which P450scc can synthesize pregnenolone that determines substrate supply 
in subsequent reactions.   
Pregnenolone then serves as the primary substrate for production of all steroids.  
As pregnenolone levels decrease, so do levels of testosterone and estradiol.  Additionally, 
since pregnenolone also serves as a substrate for cortisol, stress has the risk to exacerbate 
the crisis of low pregnenolone and by association, cholesterol.  These factors combine to 
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suggest that atorvastatin can have endocrine disrupting effects by altering the production 
of cholesterol critical for steroid synthesis.  
1.5 Amphibian Toxicology. 
Some amphibians, including Xenopus laevis, have an increased sensitivity to 
aquatic toxins due to cutaneous respiration (Feder & Burggren, 1985).  Pre-
metamorphosis tadpoles use gills and cutaneous respiration to supplement oxygen needs 
due to the high metabolic demands of metamorphosis.  This provides an additional 
exposure route to aquatic toxins and allows for greater potential for uptake into the 
bloodstream.  This is particularly problematic with regards to cutaneous respiration as the 
cutaneous membrane in these amphibians provides little barrier to environmental 
xenobiotics.  As a result, amphibians have an enhanced sensitivity to chemicals in water 
(ASTM INTERNATIONAL, 2012).  
If statins act in a similar way in amphibians as they do in humans, environmental 
exposure to atorvastatin could produce hypocholesterolemia, resulting in a net reduction 
of steroid hormone production, endocrine disruption, and at its most extreme, alteration 
of sexual differentiation and metamorphosis.  Cholesterol is the primary substrate used in 
the endogenous production of testosterone, and estradiol (Miller & Auchus, 2011).  In 
amphibians, endocrine disruption has been shown to alter sex ratios by affecting gonad 
differentiation (Miyata & Kubo, 2000; Ohtani, Miura, & Ichikawa, 2000; Yu, Hsu, Ku, 
Chang, & Liu, 1993).  Many hormones produced via the cleavage of cholesterol also 
drive the physiological processes for embryonic development and metamorphosis.  A 
recent study in zebrafish showed a 37% reduction in cholesterol, a 71% reduction in 
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cortisol, a ~60% reduction in testosterone, and a ~20% reduction in estradiol as a result of 
atorvastatin exposure (Al-Habsi, Massarsky, & Moon, 2015).  
1.6 Amphibian Development. 
Amphibians display a unique developmental apparatus that can be useful for 
toxicity studies: metamorphosis.  In 1967 Nieuwkoop and Farber published “Normal 
table of Xenopus laevis”.  This book served as the springboard into amphibian genetics 
and teratogenesis assays.  It laid out 66 developmental stages complete with criteria for 
morphological analysis that could be used to determine growth stage in a non-invasive 
manner.  It defined times to each developmental stage at varying temperatures, making it 
possible for researchers to determine alteration of amphibian development on a large-
scale basis and compare effects across laboratories. 
Amphibians pass through four broad and generalized stages during development 
(Figure 1.4).  The embryonic stage is immediately following fertilization, and during this 
time, embryos undergo cleavage, blastulation, gastrulation, neurulation, and tail-budding.  
Upon completion of the embryonic stage, the animals are free swimming and feeding 





Figure 1.4 Developmental stages of amphibians with hormone mediation of 
metamorphosis. 
Taken from: http://www.mun.ca/biology/desmid/brian/BIOL3530/DEVO_13/ch13f19.jpg 
Following the completion of the embryonic stages, the embryos transition into the 
tadpole stage.  The climax of this stage is defined primarily by metamorphosis.  During 
metamorphosis, tadpoles undergo several progressive and regressive changes and 
extensive tissue remodeling.  Hindlimb and forelimb development moves to completion, 
and the tail resorbs into the body.  Gills are resorbed into the body, and the lungs become 
the primary respiratory organ.  This stage comes with a variety of hormonal changes 
necessary for engaging the appropriate cellular response for tissue differentiation. 
Regulatory control of metamorphosis is mediated by the release of thyroxine (T4) 
and triiodothyronine (T3) by the thyroid (Gilbert, 2007).  Prolactin delays the onset of 
metamorphosis until levels of T3 and T4 exceed the levels of prolactin.  This creates a 
positive feedback loop in that the high levels of T3 and T4 stimulate further release of T3 
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and T4 to push the animal through metamorphosis (Figure 1.4).  Recent studies have 
shown an interaction between estrogen and testosterone levels with respect to thyroid 
function.  The presence of high estrogen levels in thyroid tissues has been shown to cause 
cell proliferation, and negatively affect production of thyroid hormones(Santin & 
Furlanetto, 2011).  Low levels of testosterone have also been shown to inhibit thyroid 
secretion of T3 and T4 (Meikle, 2004).  It is the interaction between the thyroid and sex 
steroids that is a cause of concern with respect to frogs exposed to statins in the 
environment, specifically alteration of testosterone and estrogen levels in 
metamorphosing tadpoles.  The interaction between sex steroids and the secretion of T3 
and T4 suggests that alteration of hormone concentrations has the potential to alter 
metamorphic rates. 
I hypothesized that chronic exposure to low concentrations of atorvastatin in 
water has an adverse effect on production of steroids regulating growth and development 
of X. laevis.  This was tested via a series of toxicity assays.  These assays first examined 
atorvastatin efficacy by evaluating biomarkers of exposure in a tightly controlled 
environment at doses well above environmental relevance.  Once the efficacy of the drug 
was verified, a battery of assays were used to evaluate environmentally relevant doses 
across multiple life stages to examine the effects of atorvastatin exposure on amphibian 
steroidogenesis.  Measures for the target and non-target effects of atorvastatin on X. 
laevis will be expression of several relevant genes, cholesterol measurement, and 





1.7 Experimental Design. 
The complete experimental design consisted of 3 distinct assays intended to test 
the effect of atorvastatin at different developmental endpoints and maximize data 
collection.   
The first assay was used to determine the effects and verify the biomarkers used 
in follow-on assays.  This assay followed the ASTM assay protocol for the Frog Embryo 
Teratogenesis Assay Xenopus (FETAX)(ASTM INTERNATIONAL, 2012) with minor 
modifications to assay termination to preserve samples for molecular analysis as 
described in the materials and methods chapter.  This assay is performed at extremely 
high concentrations as defined by the FETAX protocol.  The intent behind this assay was 
to elicit an effect and measure that effect.  This assay served to hone tools for future data 
analysis and validate biomarkers for assays at lower concentrations. 
The second assay was a chronic tadpole metamorphosis assay.  This experiment 
was a 60-day chronic flow-through exposure under environmentally relevant 
concentrations of atorvastatin.  Briefly, tadpoles (NF47) were exposed continuously for 
60 days and time to and through metamorphosis was measured.  At termination, tadpole 
liver tissue was taken for follow up molecular analysis.  This experiment showed effects 
of chronic, low concentration exposures of atorvastatin in water to metamorphosing 
tadpoles. 
The final assay was a chronic 60-day exposure of male and female adults to 
environmentally relevant concentrations of atorvastatin in water.  This aqueous exposure 
showed the long term, chronic effects of exposure to atorvastatin.  Endpoints in this assay 
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include transcriptional analysis of assigned biomarkers of exposure, and quantification of 




CHAPTER II – MATERIALS AND METHODS 
2.1 Introduction. 
The complete experimental design consisted of three distinct experimental assays. 
The FETAX assay was employed to evaluate the effects of high doses of atorvastatin on 
developing Xenopus sp. embryos.  The metamorphosis assay integrated organismal 
responses determined from the FETAX to determine the effects of aqueous atorvastatin 
exposure at environmentally concentrations on metamorphosing tadpoles.  Finally, the 
adult exposure evaluated the effects of chronic low concentrations of atorvastatin on adult 
X. laevis. 
2.2 FETAX. 
The Frog Embryo Teratogenic Assay (FETAX) is an acute 96-hour exposure to 
evaluate the effects of xenobiotic exposure during early life stages.  The protocols and 
procedures used in this experiment were a modification of the “Standard Guide for 
Conducting the Frog Embryo Teratogenesis Assay-Xenopus (FETAX)”(ASTM 
INTERNATIONAL, 2012).  The FETAX follows the strictest of standards based on 
decades of research data, as such, these standards are ideal for testing the response of 
Xenopus sp. to xenobiotic exposure.  The FETAX uses primarily morphometric data 
endpoints to determine growth and developmental effects of exposure.  The standard 
protocol advises fixing the tadpoles in formalin for later analysis.  This termination 
protocol would not preserve tissue in a manner useful for follow-on molecular analysis.  
In order to preserve the tissue in a manner more conducive to our needs, I have modified 
the termination procedure by preserving the samples either in RNALater for later 
extraction and analysis or by flash freezing for cholesterol analysis.  
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Briefly, embryos were collected and dejellied immediately following fertilization.  
Normal embryos between NF stage 8 and 11 were selected and randomly distributed into 
petri dishes.  A selection of 5 increasing concentrations, determined using the ASTM 
selection criteria, plus a control were set-up with 4 replicates.  The embryos were then 
allowed to grow out for 96 hours in a temperature-controlled incubator at 28°C under 
constant supervision.  At termination, images of each tadpole were taken for 
morphometric analysis, and whole organisms were flash frozen for cholesterol 
quantification or stored in RNALater for qPCR analysis. 
2.3 Metamorphosis Assay. 
The metamorphosis experiment was a chronic 60-day exposure to evaluate effects 
during metamorphosis and growing into adulthood.  The test was conducted with a 
control and 3 treatments (n=30) in duplicate.  Frogs were exposed to aqueous 
concentrations of atorvastatin for the duration of the 60-day experiment. At termination, 
the froglets were staged to allow for morphometric analysis, and liver samples were taken 
for cholesterol quantification and qPCR analysis. 
Tadpoles were commercially purchased from Xenopus Express and stage selected 
to be NF 47 at shipment.  Tadpoles were shipped overnight and acclimated to room 
temperature upon arrival.  Following acclimation, tadpoles were stage selected again to 
be NF 47 at test initiation.  Tadpoles were then sorted into 100 mL beakers (n=40) and 
the beakers were covered with nytex mesh.  The beakers were then placed into the flow 
through exposure facility at the University of Southern Mississippi’s Gulf Coast Research 
Laboratory.  This unique facility allows continuous flow through exposures at a wide 
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range of operating parameters.  Table 2.1 describes the operational parameters of the 
exposure system for the duration of this experiment. 
 






Stock solutions were prepared by first diluting atorvastatin calcium (CAS#: 
344423-98-9) into DMSO at a concentration of 250 g/L.  This primary stock was then 
further diluted into a 10 g L-1 working stock for stock renewals.  This working stock was 
then diluted into appropriate stock concentrations and volumes for exposure chamber 
protocols. 
The exposure facility then continuously dilutes stock solutions and flows it 
through the exposure tanks as the prescribed flow rate.  Water samples were taken at 
initiation, 30 days, and termination.  These water samples were analyzed by Mississippi 
State Chemistry Laboratory using LC/MS-MS for validation of dosing concentrations. 
Water quality was monitored continuously using the built-in sensor array and 
verified daily using a handheld YSI Quatro.  As tadpoles grew, they were moved to a 
larger enclosure weekly.  Tadpoles were fed Xenopus Express tadpole crumble food for 
the duration of the experiment.  Initially, 1 pellet of crumble food per tadpole was left to 
soak for 1 hour in clean system water and once dissolved, the entirety of the liquid food 
Temperature 22° C 
Salinity 0.15 ppt 
Dissolved 
Oxygen 
8.5 mg L-1 
pH 7.5 
Flow Rate 1.5 L hr-1 






was fed to the tank.  Animals were left at room temperature outside of flow-through 
conditions for 1 hour following feeding then returned to the flow-through chamber.  As 
the tadpoles grew, an increasing amount of food was fed, and whole pellets were fed after 
tadpoles had transitioned from gills to lungs.  Tanks were cleaned biweekly by siphoning 
out waste and detritus.  Frogs were observed daily, and any injured or dead frogs were 
removed from the tank. 
2.4 Adult Chronic Assay. 
The chronic adult exposure was a 60-day flow-through exposure intended to 
investigate the response of adult frogs to chronic, low dose aqueous exposures at 
environmentally relevant concentrations.  Frogs were ordered from Xenopus Express and 
shipped overnight.  Upon arrival frogs were placed in 1cm of water and allowed to warm 
to room temperature for 30 minutes.   
After the initial warming period, frogs were placed in individual 1 L tanks of 
water and visually inspected for any sign of injury or illness.  Following visual 
inspection, frogs were transferred to 20 L holding tanks segregated by sex.  The animals 
were physically isolated in the holding tanks, however both tanks shared the same water.  
The holding tanks were 30 L continuous flow holding tanks running at a flow rate of 
approximately 1.5 L/hr.  Tank water was UV sterilized, mechanically filtered, and 
temperature adjusted artesian well water.  Water testing performed within 1 year of the 
experiment verified that the water was within physical and chemical limits for 
experimentation.  The holding tanks were maintained at 21 ±3°C and on a 12h day/12h 
night light cycle.  Frogs were fed measured amounts of Zeigler Xenopus Diet 3 times 
weekly.  Males received 3 pellets each per feeding, and females received 6 pellets each 
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per feeding.  Approximately one hour after feeding, tanks were cleaned, and any uneaten 
food was siphoned from the tanks.   






Similar to the metamorphosis experiment, this experiment was run in the flow-
through exposure facility at the University of Southern Mississippi’s Gulf Coast Research 
Laboratory.  Exposure facility flow-through parameters can be found in Table 2.2.  Water 
quality was continuously monitored using the facility’s in-house sensor array and 
checked daily using a YSI Quatro.  Water samples were collected from the effluent tube 
of the exposure tanks at set-up, 4 weeks, and termination.  These samples were sent to 
Mississippi State Chemical Laboratory for analysis via LC-MS/MS.  At termination, 
blood was drawn via cardiac puncture and plasma was separated and frozen, then the 
frogs were euthanized via double pith and cervical dislocation.  Immediately following 
euthanasia, frogs were dissected, and liver, kidney, digestive tract, gonads, and spleen 
were removed for follow up analysis.  
Preserved samples were then used for qPCR, cholesterol analysis, and sex steroid 
analysis.  Samples used for qPCR underwent mRNA extraction using spin column 
extraction (Qiagen #74106) and reverse transcription to cDNA using a RevertAid First 
Strand cDNA Synthesis Kit (Thermo #K1621).  Extracted cDNA was then used for qPCR 
Temperature 22° C 
Salinity 0.15 ppt 
Dissolved 
Oxygen 
8.5 mg L-1 
pH 7.5 
Flow Rate 1.5 L hr-1 






to determine gene dysregulation as described in the molecular techniques.  Samples 
tested for cholesterol and sex steroids used associated protocols described in the 
molecular techniques section of this document.   
2.5 Molecular Techniques. 
Spin column RNA isolation was performed following the RNeasy Mini Kit 
(Qiagen #74106).  Following extraction and isolation of mRNA, samples were reverse 
transcribed using the RevertAid First Strand cDNA Synthesis kit (Thermo #K1621).  
Following cDNA synthesis, samples were used in follow up qPCR reactions.  Primers 
were designed using Primer3 and purchased from Integrated DNA technologies.  Primer 
efficiencies are listed in Table 2.3.  Quantitative PCR was performed on an Applied 
Biosystems 7500 Fast Real-Time PCR system using Fast SYBR Green Mater Mix 
(Applied Biosystems #4385612) and associated protocol. 
Table 2.3 Primer efficiencies for primers used in qPCR reactions. 
Lipid extraction from tissues for follow-on cholesterol quantification was 
performed using a chloroform free Lipid Extraction Kit (abcam #ab211044).  This 
protocol was only used in the FETAX assay for extraction of whole-body cholesterol 
from tadpoles.  Cholesterol quantification was performed on plasma as well as tissue 
Primer Sequence Efficiency 
18s CGT CGC TAC TAC CGA TTG GA 
CGC AGG TTC ACC TAC GGA AA 
96.45 % 
hmgcr TGA TTG GCC GTA GGA AGA GC 
TGG TGA TTG TGA AGC TCG GG 
95.68 % 
cyp3a4 GAG CCC ATT ACT CAT CTT AGT GGT 
CAC GTC CCG AGT GAT CTC C 
96.06% 
cyp19a1 TGC ACG TCT CCT AAC TTT ACT GG 




extract using Amplex Red Cholesterol Assay Kit (Thermo #A12216) and associated 
protocol. 
Testosterone and estradiol concentrations in plasma were measured using a 
Testosterone ELISA Kit (abcam #108666) and 17 beta Estradiol ELISA Kit (abcam 
#ab108667) respectively.  These kits are designed for use in human plasma, therefore 
both ELISA kits were validated using X. laevis plasma to verify hormone binding to the 
antibody.  Plasma used in the testosterone ELISA was diluted 100x and plasma for the 
estradiol ELISA was dilute 1000x to keep all sample RFU measurements within the 
standard curve. 
RNA sequencing was performed on 6 samples at the University of Colorado’s 
Core Microarray facility.  The six samples were selected from the metamorphosis assay 
and consisted of three control samples and three samples from the 4.4 ug L-1 treatment.  
Briefly, RNA was isolated using the previously described protocol.  Verification of RNA 
integrity was performed using a NanoDrop 2000 to evaluate purity, and an Agilent 
Bioanalyzer 2100 to evaluate RNA integrity.  Once purity and integrity were determined 
to be acceptable for sequencing, samples were shipped overnight in dry ice to the 
University of Colorado.  RNA sequencing and library preparation was performed on a 
NovaSEQ 6000 using 2x150 paired end reads.   
CLC Genomics Workbench (CLC) was used for initial data preparation and 
mapping to the X. laevis reference genome (NCBI accession number: 
GCA_001663975.1).  Data preparation included removal of failed and low-quality reads 
as well as adaptor trimming.  Differential gene expression analysis was then performed 
on the control versus the treatment group. 
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Ingenuity Pathway Analysis (IPA) was used for determination of pathway 
dysregulation.  One of the limitations of IPA is that reference genes must be mapped to 
their human ortholog as pathway data is not available for the amphibian genome.  Since 
molecular pathways are widely considered to be highly conserved across taxa, this 
limitation was deemed to have a minimal impact on pathway analysis.  The FDR cutoff 
was set to 0.05, and pathway analysis was determined using expression fold change 




CHAPTER III – FROG EMBRYO TERATOGENESIS ASSAY, XENOPUS 
3.1 Introduction 
The purpose for the FETAX assay in this project was to evaluate the uptake, 
activity, and efficacy of atorvastatin in the amphibian model.  Uptake was defined as 
integration into the bloodstream.  This is accomplished primarily by either osmosis via 
cutaneous respiration or Cyp3a4 mediated transport across the intestinal lumen.  
Atorvastatin activity was defined by upregulation of hmgcr and was a measure of 
substrate binding activity allowing the drug to produce both target and non-target effects.  
Substrate efficacy was defined as target effects produced downstream of the site of 
activity and was be measured via cholesterol concentrations in tissue. 
As previously discussed, the FETAX is an acute 96-hour assay.  It is a highly 
sensitive, highly studied experimental protocol useful in determining growth and 
developmental abnormalities.  Our purpose for choosing the FETAX protocol is its tight 
experimental parameters and its ability to rapidly evaluate the effects of atorvastatin 
exposure.  Embryos were collected and dejellied immediately following fertilization.  
Normal embryos between NF stage 8 and 11 were selected and randomly distributed into 
petri dishes.  A selection of 5 increasing concentrations determined from the FETAX 
experimental protocol, plus a control and carrier control were set-up with replicates 
(Figure 3.1).  The embryos were grown out for 96 hours in a temperature-controlled 
incubator at 28C under constant supervision with water changes every 24 hours.  At 
termination, images of each tadpole were taken for morphometric analysis, and the whole 
organism was preserved for cholesterol quantification and qPCR analysis by flash 




Figure 3.1 FETAX experimental design. 
Frogs were bred as a single mated pair, and only the embryos from one single pair 
were used in the experiment.  Frogs were injected with 350 and 700 IU human chorionic 
gonadotropin (HCG) for males and females respectively.  Injections were given into the 
dorsal lymph sac at a concentration of 1000IU/mL in sterile 0.9 % NaCl using a 26-gauge 
needle.  Twelve hours following injection, eggs were collected and dejellied immediately.  
De-jellying embryos was performed as soon as egg collection was complete.  
Eggs were transferred to a clean 1L beaker and swirled for ~2 minutes using de-jellying 
solution described in the protocol(ASTM INTERNATIONAL, 2012).  Once the jelly coat 
was sufficiently removed, embryos were rinsed 3 times in FETAX solution(ASTM 
INTERNATIONAL, 2012) and transferred to petri dishes for staging.  
During staging and selection, embryos were double staged prior to selection for 
experimentation.  First embryos were selected for normal cleavage consistent with “Atlas 



































NF 8 and NF 11.  If selected, embryos were moved to petri dishes of 25 embryos per dish 
containing 10 mL FETAX solution.  
Petri dishes were then randomly assigned to replicate groups.  There were four 
control replicates, four carrier control replicates, and 2 dishes for each concentration of 
0.003696, 0.00924, 0.0231, 0.03696, and 0.059136 mg mL-1 respectively.  Dishes were 
then spiked with atorvastatin dissolved in DMSO, or DMSO only for carrier control.  
Spike solution did not exceed 1% of FETAX solution volume, and was temperature 
adjusted to 28C prior to introduction for petri dishes.  
Dishes were then stored overnight in an incubator at 28C until renewal.  Test 
solution was completely replaced every 24 hours.  Prior to renewal, the pH of the control 
and the highest dose dishes was measured to monitor for large pH differences in the 
presence of toxin.  For renewal, all test solution was removed using a pasteur pipette with 
an orifice large enough to allow the embryos to pass through to prevent damage.  Next, 
new test solution was then immediately poured into the dish.  Dishes were then returned 
to the incubator.  This process was repeated daily for the duration of the 96-hour 
experiment.  
At test completion, dishes were photographed using a Nikon SMZ1500 dissecting 
microscope fitted with a Nikon DXM1200C digital camera and embryos were euthanized 
using a 2.5% v/v tricaine solution.  Embryos were then transferred into 1.5 mL 
microcentrifuge tubes containing 1 mL of RNALater.  Tubes were allowed to rest at 
room temperature for one hour to allow complete infiltration of preservative, then 
transferred into -80C until downstream analysis.  
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Validation of test concentrations was performed by spectrofluorimeter using a 
previously validated method (Sharaf El-Din, Salama, Nassar, Attia, & Kaddah, 2012).  
This method allowed simple, and rapid, same-day analysis of FETAX test solution to 
monitor and verify test concentrations. 
3.2 Endpoints and Protocols 
Preserved embryos were used for qPCR and cholesterol analysis.  Embryos used 
for qPCR underwent mRNA extraction using spin column and reverse transcription to 
cDNA.  Extracted cDNA was then used for qPCR to determine gene dysregulation as 
described in the molecular techniques section of this manuscript.   
The FETAX assay in this project was intended to verify that the response of the 
amphibian model is similar to the response in humans.  As such, the biomarkers selected 
for this assay were carefully designed to map directly to the human response to 
atorvastatin exposure.  The protein encoded by cyp3a4 is responsible for transporting 
atorvastatin from the digestive system into the blood stream.  Studies have shown that in 
the presence of atorvastatin, cyp3a4 will be transcriptionally upregulated in order to 
maintain sufficient enzyme in circulation (Willrich et al., 2013).  In the FETAX assay I 
expected to see a similar response in X. laevis with upregulation of cyp3a4 indicating 
uptake of atorvastatin.  Atorvastatin is a competitive inhibitor hmgcr, and exposure 
causes transcriptional upregulation of the genes encoding for Hmgcr (Brown & 
Goldstein, 2009). This provides a useful biomarker indicating activity of atorvastatin.   
Finally, the target effect of atorvastatin is a reduction in circulating cholesterol 
(Lennernäs, 2003).  While this study is intended to investigate non-target effects of 
atorvastatin, evaluating cholesterol levels serves as a measure of efficacy by determining 
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if atorvastatin has reached circulatory concentrations high enough to elicit the targeted 
response, in this case, reduction of circulating cholesterol.  Eliciting this response is the 
primary reason for the use of concentrations many orders of magnitude above 
environmental relevance in the FETAX.  If atorvastatin functions in amphibians in the 
same manner as in humans the molecular signature should be similar to humans.  This is 
upregulation of cyp3a4 and hmgcr, and reduction of total cholesterol levels.  Once 
verified, this signature was then applied to follow-on studies for validation of atorvastatin 
dosing in chronic aqueous assays. 
3.3 Results and Discussion 
3.3.1 Water Chemistry 
Because I had previous data concerning aquatic toxicity of atorvastatin (Pfizer, 
2018), I was able to skip the range finder test, and move directly to the definitive test in 
the FETAX.  Test concentrations tested were 0.03, 0.05, 0.08, 0.10, and 0.12 mg L-1.  
These concentrations were defined based on the strict FETAX experimental protocol and 
allow future comparisons to other FETAX data.  I chose to take the lowest NOEC in the 
available data, and test concentrations ranging down from that concentration.  This 
enabled us to test at the lowest possible concentrations and was particularly useful 
considering the extremely low concentrations to be tested during the subsequent assays. 
The mean atorvastatin concentrations measured daily at each water change were 
0.0142, 0.0112, 0.0489, 0.0564, and 0.1193 mg L-1 (Figure 3.2).  The test solution fell 
into three statistically significant groups based on a One-Way ANOVA with Holm-Sidak 
pairwise comparisons (p < 0.001 F = 20.98, df = 13).  The control, carrier control, 
0.0142, and 0.0112 mg L-1 concentrations were statistically similar, however they were 
 
29 
different than all other groups.  The 0.0489 and 0.0564 mg L-1 concentrations were 
statistically similar, but significantly different than all other groups.  The highest 
concentration of 0.1193 mg L-1 was significantly different than all other groups.  Based 
on these data, molecular endpoints were evaluated for samples produced from the 0.0489 
and 0.1193 mg L-1 concentrations as these concentrations were significantly different 
from the controls. 
FETAX Atorvastatin Concentrations
Treatment

































Figure 3.2 Mean atorvastatin concentrations and standard error of atorvastatin in 
exposure water immediately prior to water change. 
Since I anticipated degradation of the atorvastatin over time for the duration of the 
experiment, I measured the concentration of atorvastatin in solution via fluorescence 
daily at water change (Figure 3.3).  Overall, atorvastatin treated water saw a general 
degradation over time.  This is expected since atorvastatin concentrations were measured 
prior to water change.  The water had been in the exposure dishes for 24 hours, and some 
degradation of the stock is not uncommon.  The highest concentrations saw the greatest 
decrease in statin levels over time.  Collectively, all samples saw a degradation at each 
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water change.  This is probably caused by stock degradation.  The FETAX protocol 
requires a single stock solution created at the beginning of the experiment and used for all 
subsequent water changes if possible, meaning that stock degradation may occur over 
time. 
FETAX Atorvastatin Concentration vs Time









































Figure 3.3 FETAX atorvastatin concentrations over time. 
3.3.2 Molecular Endpoints 
The metabolism and uptake of atorvastatin is mediated by the protein Cyp3a4.  
The qPCR data indicate statistically significant and dose dependent upregulation of 
cyp3a4 (Figure 3.4).  The control and carrier control treatments were not significantly 
different from each other but were statistically different from the atorvastatin treated 
doses base on One-way ANOVA with Holm-Sidak pairwise comparison (p < 0.001, F = 
25.56, df = 47,).  This indicates that the carrier did not have a significant effect on 
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transcriptional regulation of cyp3a4.  The atorvastatin treatments of 0.0489 and 0.1193 
mg L-1 were significantly upregulated relative to controls.  The treated groups show 
increasing upregulation as dose increased.  This significant upregulation indicates dose 
dependent metabolism of atorvastatin in the frog system as more Cyp3a4 protein is 
































Figure 3.4 Gene expression of cyp3a4 in the FETAX experiment. 
The genes encoding for Hmgcr also presented significant upregulation of 
expression patterns (Figure 3.5).  In this case, the control and carrier treatment were not 
significantly different from one another, and the lowest treatment of 0.0489 mg L-1.  The 
highest treatment of 0.1193 mg L-1 was significantly different from all other treatments.  
Upregulation of hmgcr expression was dose dependent, however upregulation of 
expression patterns was not as extreme as cyp3a4 upregulation.  The highest treatment 
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saw only 0.6833 upregulation relative to the carrier.  This is consistent with a lag time 
associated with metabolism and uptake of atorvastatin prior to the distribution of 































Figure 3.5 hmgcr expression in the FETAX experiment. 
Overall, the molecular signature of atorvastatin dosing in humans was confirmed 
in the amphibian model.  As expected, statistically significant upregulation of cyp3a4 and 
hmgcr confirmed uptake and activity of atorvastatin.  These data demonstrated Cyp3a4 
production increasing with increasing exposure concentrations resulting in statin uptake 
into the blood stream.  Additionally, hmgcr follows a similar trend of upregulation, and 
this linkage confirms that cyp3a4 upregulation is driving hmgcr upregulation as 
mevalonate is depleted and additional Hmgcr enzyme is created to attempt to convert 
additional mevalonate to fill this gap. 
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3.3.3 Cholesterol ELISA 
Whole tissue cholesterol levels were analyzed via Amplex Red Cholesterol 
Assay.  Samples were first extracted using a chloroform free lipid extraction kit (abcam 
#ab211044).  Briefly, five tadpoles from each replicate were pooled (n=5) and 
homogenized prior to lipid extraction, and pooled samples were then analyzed for total 
cholesterol content.  Replicates were then combined by treatment and mean cholesterol 
concentrations and standard deviation were evaluated against the standard curve 
associated with the previously discussed protocol. 
Total cholesterol levels in the FETAX experiment showed a reduction in total 
cholesterol levels (Figure 3.6).  One-way ANOVA with Holm-Sidak pairwise comparison 
of measured cholesterol (p < 0.001 F = 56.54, df = 64,) levels in the control and carrier 
control were not significantly different indicating the DMSO carrier had no effect on total 
cholesterol levels in the tadpoles.  The lowest atorvastatin treatment of 0.0142 mg L-1 was 
not significantly different from the controls, however all higher concentration treatments 
were significantly different from the controls, and each other.  This is indicative of the 
target action of atorvastatin dosing.  These data show that a 96-hour exposure to statins at 
concentrations well above environmental relevance can elicit the targeted response of 
significant reduction in cholesterol.  Furthermore, this reduction is achieved far faster 
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Figure 3.6 Total cholesterol levels of tadpoles in FETAX. 
The number on each bar represents the number of samples represented in the data set. 
3.4 Conclusions 
The intent of the FETAX in this project was to confirm uptake, activity, and 
efficacy of atorvastatin on X. laevis. The data collected and analyzed show that Cyp3a4 
mediated uptake of atorvastatin and competitive inhibition of Hmcgr results in dose-
dependent reduction of total cholesterol levels in tadpoles exposed to atorvastatin.  These 
results are consistent with the previously discussed molecular and physiological signature 
associated with atorvastatin exposure in humans.  These results lay the groundwork for 
the two follow-on exposures at environmentally relevant concentrations of atorvastatin 
and provide baseline reference data for predicting non-target effects of atorvastatin 
exposure in X. laevis. 
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CHAPTER IV – METAMORPHOSIS ASSAY 
4.1 Introduction 
The objective of the metamorphosis assay was to evaluate the effects of chronic, 
low concentrations of aqueous atorvastatin on developing tadpoles with additional 
emphasis on endocrine disruption. This assay used the molecular fingerprint confirmed in 
the FETAX to verify atorvastatin exposure and adds additional analysis of cyp19a1 to 
evaluate the endocrine disruption potential of atorvastatin exposure.  In addition, 
morphometric analysis of growth and developmental parameters was used to monitor for 
overt endocrine disruption and teratogenesis. 
This experiment was a 60-day chronic flow-through exposure and concentrations 
for this experiment were 0.2, 0.7, and 0.5 μg L-1 plus a control and there were two 
replicates of each concentration (n=40).  Mortality was measured for the duration of the 
experiment only for confirmation of sub-lethal dosing.  Due to the highly lipophilic 
nature of atorvastatin, DMSO was used as a solvent to assist the atorvastatin transfer into 
water.  Atorvastatin was first diluted into DMSO to make the primary stock solution.  
The primary stock solution was then further diluted into water to created stock 
concentrations at the desired level.  The same stock solution was used throughout the 
duration of the 60-day chronic exposure.  Stock solution was renewed every 48 hours, 
and the primary stock was stored at -20 C to prevent degradation for the duration if the 
test. 
4.2 Endpoints and Protocols 
The endpoints for this experiment were morphometric analysis of growth and 
developmental parameters, and molecular analysis via qPCR of the previously described 
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biomarkers.  Due to the small size of post-metamorphosis frogs, it was not possible to 
draw blood for cholesterol or steroid analysis. 
Molecular biomarkers for this experiment were cpy3a4, hmgcr and cyp19.  
Statistical analysis of all qPCR data was performed using a One-way ANOVA with 
Holm-Sidak pairwise comparisons.  The previously discussed biomarkers of cyp3a4 and 
hmgcr were used to evaluate uptake and activity of atorvastatin in this exposure.  Since 
the post-metamorphosis frogs were too small to collect sufficient quantities of blood for 
cholesterol analysis, yet far too large for whole tissue analysis of cholesterol content, 
these two biomarkers will serve to confirm the efficacy of atorvastatin in this exposure by 
confirming the same directionality of transcriptional dysregulation.   
The addition of cyp19a1 as a biomarker to evaluate endocrine disruption allows 
additional molecular data to support the morphometric analysis.  While the morphometric 
analysis can detect overt, severe effects of endocrine disruption, cyp19a1 is far more 
sensitive in detection of changing sex steroid levels, an early predictor of endocrine 
disruption.  As previously discussed, the Cyp19a1 protein is responsible for conversion of 
testosterone to estradiol.  This conversion happens as a negative feedback loop when 
faced with declining estradiol levels.  As less estrogen is available to bind the estrogen 
receptor, estrogen receptor related proteins dissociate from the estrogen receptor complex 
and bind to the promotor region of cyp19a1.  This promotes transcription of the Cyp19a1 
enzyme to generate more enzyme for conversion of testosterone to estradiol.  It is this 
negative feedback loop that makes cyp19a1 an attractive biomarker for evaluating 
changing sex steroid levels.  Upregulation of cyp19a1 will be indicative of activation of 
this feedback loop due to declining estradiol levels relative to control. 
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Morphometric analysis included measurement of snout-vent length, mass, and NF 
stage.  Snout-vent length and mass were recorded at experiment termination.  Snout-vent 
length was measured using stainless steel analog calipers on live frogs.  Mass was 
recorded by placing the live frog in a tared beaker of water and recording mass.  Growth 
stage (NF stage) was measured visually by only one observer.  As these were post 
metamorphosis frogs, microscopy and blind observers were not deemed necessary due 
the relative ease of determining growth stage on frogs post-metamorphosis. 
4.3 Results and Discussion 
4.3.1 Water Chemistry 
Water samples were taken at set-up, the midpoint, and termination of the 
experiment.  These samples were collected directly from the effluent lines for each 
replicate tank.  The samples were then frozen and shipped to the Mississippi State 
Chemical Laboratory for analysis.  The results of this independent analysis of atorvastatin 
concentrations in test water served to validate test parameters. Figure 4.1 contains 
average concentrations and standard deviation (represented by error bars) of atorvastatin 
in exposure water.  The low treatment was not significantly different, based on One-way 
ANOVA (p < 0.001 F = 612.699, df = 23,), from the control, and thus was not used in 
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Figure 4.1 Atorvastatin concentrations in exposure water for the metamorphosis 
experiment. 
The average water quality measurements and standard deviations are reported in 
figure 4.2.  Water quality parameters were monitored continuously by the toxicology 
assay chamber, and randomly verified using hand held equipment daily.  Ammonia levels 
were 0 ppt for the duration of the experiment and are not represented in graphs.  All 
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Figure 4.2 Exposure tank water quality parameters by treatment. 
4.3.2 Molecular Analysis 
At termination, liver samples were collected, and flash frozen for follow-on 
molecular analysis.  The liver tissue was extracted and reverse transcribed following the 
previously described protocols. 
Expression of cyp3a4 is a biomarker of exposure to atorvastatin.  As previously 
discussed, cyp3a4 is used an indicator of atorvastatin uptake.  Figure 4.3 shows 
differential gene expression of cyp3a4 in tadpoles exposed to atorvastatin the 
metamorphosis experiment (p < 0.05, F = 12.59, df = 8,).  These data indicate slight 
upregulation of cyp3a4 relative to control in both the 0.7 and 4.4 ug L-1 concentrations, 
however this effect is not statistically significant.  The reason for such insignificant 
upregulation may be differing exposure routes.  As previously discussed, the primary site 
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of cyp3a4 mediated uptake occurs in the lining of the digestive tract.  This is somewhat 
problematic in that the gene expression analyzed here is from liver tissue.  However, 
studies have shown that cyp3a1 upregulation is also seen in the liver when an organism is 
exposed to atorvastatin, but not to the same extent as in digestive tissue.  Additionally, 
this is an aqueous exposure that is bypassing the digestive tract and entering systemic 
circulation via cutaneous respiration as well as uptake at the gills pre-metamorphosis.  In 
light of this, it is sensible to evaluate cyp3a4 expression levels in the liver, and 
unsurprising that very little upregulation of cyp3a4 expression is evident in this exposure.  
The 4.4 ug L-1 concentration showed less extreme upregulation than the 0.7 ug L-1 
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Figure 4.3 Differential expression of cyp3a4 in metamorphosing tadpoles exposed to the 
indicated concentrations of atorvastatin. 
Expression of hmgcr served as a biomarker indicating activity of atorvastatin.  
Figure 4.4 shows differential gene expression of hmgcr in tadpoles exposed to 
atorvastatin in the metamorphosis experiment (p < 0.05 F = 20.34, df = 8,).  These data 
indicate upregulation of hmgcr relative to controls for both the 0.7 and 4.4 ug L-1 
concentrations.  The expression levels were not statistically different from one another 
indicating similar activity of atorvastatin despite differences in cyp3a4 expression levels 
previously discussed.  This upregulation in hmgcr expression levels relative to controls 
indicates atorvastatin competitively inhibiting Hmgcr.  When viewed in conjunction with 
the cyp3a4 data, it becomes apparent that despite atorvastatin bypassing the digestive 
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exposure route, cutaneous respiration still allows significant enough levels of atorvastatin 
in the blood to maintain efficacy. 
 
Differential Expression of hmgcr
Metamorphosis Experiment
60 Day Aquatic Exposure






























Figure 4.4 Differential expression of hmgcr in metamorphosing tadpoles exposed to the 
indicated concentrations of atorvastatin. 
The protein encoded by the cyp19a1 gene is responsible for conversion of 
testosterone to estradiol.  This gene serves a biomarker indicating dysregulation of the 
steroidogenesis pathway.  Figure 4.5 shows differential gene expression of cyp19a1 in 
liver tissue of post-metamorphosis froglets exposed to atorvastatin through 
metamorphosis.  These data show statistically significant, dose dependent, upregulation 
cyp19a1.  As previously stated, this upregulation is indicative of declining estradiol levels 
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in the frogs.  The dose dependent trend of cyp19a1 indicates that as atorvastatin 
concentrations in water increase, the extent to which cyp19a1 transcription is upregulated 
also increased.  This is occurring despite similar activity levels in hmgcr transcription 
rates indicating that while the cholesterol biosynthesis pathway displays a degree of 
resistance to dysregulation, the steroidogenesis pathway is still altered dramatically.  The 
cholesterol biosynthesis pathway is highly conserved and tightly regulated and is 
surprisingly resistant to xenobiotic alteration of transcriptional profiles, however, as seen 
in these data, only slight alteration of cholesterol biosynthesis is enough to significantly 
alter steroidogenesis. 
Differential Expression of cyp19a1
Metamorphosis Experiment
60 Day Aquatic Exposure






























Figure 4.5 Differential expression of cyp19a1 in metamorphosing tadpoles exposed to the 
indicated concentrations of atorvastatin. 
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4.3.3 Morphometric Analysis 
In addition to the previously discussed molecular endpoints, this experiment 
included morphometric endpoints.  These endpoints were length, mass, and NF stage.  
NF stage was measured two times during the experiment, at set-up and take-down.  
Figures 4.6 and 4.7 show mean frog length and mass respectively with standard deviation 
represented by error bars.  These data showed no significant difference in either 
endpoints based on One-way ANOVA (p = 0.136 F = 2.01, df = 173) indicating aqueous 
exposures at these concentrations have no significant effect on tadpole growth.  Figure 
4.8 shows mean NF developmental stage of post-metamorphosis tadpoles in this exposure 
(n=40/treatment).  While a slight downward trend is evident, the difference is not enough 
to be statistically significant based on One-way ANOVA (p = 0.981, F = 0.019, df = 
119).  The lack of error bar on the control is due to the deviation being 0 as all animals in 
the control tanks completed metamorphosis.  The downward trends in the treated tanks 
are driven by a small number of tadpoles that did not complete metamorphosis.  As 
previously mentioned, this trend was not significant enough to indicate developmental 
dysfunction, however, this does warrant further observation in the future. 
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Figure 4.6 Mean length and standard deviation of tadpoles treaded with aqueous 
atorvastatin (n=40 per treatment). 




















Figure 4.7 Mean wet mass and standard deviation of tadpoles treaded with aqueous 
atorvastatin (n=40 per treatment) 
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Figure 4.8 Mean NF developmental stage of post-metamorphosis tadpoles exposed to 
aqueous atorvastatin. 
4.3.4 RNA Sequencing and Bioinformatic Analysis 
In addition to the traditional qPCR analysis of gene expression, sequencing of 
total RNA transcripts and subsequent bioinformatic analysis was employed for the 
metamorphosis assay to evaluate dysregulation of molecular pathways associated with 
exposure to aqueous atorvastatin.  Figures 4.9 and 4.10 show the top 30 most 
dysregulated canonical pathways as determined by IPA analysis of differentially 
expressed genes in the data set.  The darker orange and red colors indicate activation of 
the pathway, and the corresponding shades of blue indicate suppression of the pathway.  
The grey bars indicate dysregulation; however, the software was unable to determine 
directionality in terms of activation or suppression.  This is most often due to individual 
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genes in the pathway not behaving as predicted.  For instance, if the software sees 
upregulation in a specific gene, and predicts corresponding upregulation of a subsequent 
gene in response, but instead the data indicate downregulation of that downstream gene, 
then the software is unable to determine directionality.  This type of result should not be 
viewed as a negative result or lack of data, but rather it indicates that the pathway has 











Figure 4.10 Top 30 dysregulated pathways (continued) in X. laevis exposed to aqueous 
atorvastatin during metamorphosis. 
These data indicate extensive DNA damage and associated repair mechanisms for 
responding to damage.  Thirteen of the top 30 significantly dysregulated pathways are 
associated with this DNA damage response, indicating extensive DNA damage repair in 
metamorphosing tadpoles exposed to aqueous atorvastatin.  Additionally, two of the top 
30 pathways indicate oxidative stress response.  This points to generation of reactive 
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oxygen species (ROS) causing DNA damage in exposed tadpoles.  The link between 
ROS generations and DNA damage is well supported in literature (Friedberg, McDaniel, 
& Schultz, 2004), as is the link between atorvastatin and ROS generation (Bouitbir et al., 
2011, 2016).  Interestingly, human biomedical literature suggests the opposite effect of 
reduction of oxidative stress primarily driven by a reduction in endogenous production of 
cholesterol resulting in decreased metabolism of fatty acids and subsequently decreased 
generation of ROS (Briones et al., 2009; Ceriello et al., 2005; Sugiyama et al., 2005).  
These opposing findings suggest differing responses to atorvastatin in humans versus rats 
in the cited studies, and amphibians in this study.  This gap in understanding warrants 
future investigation into causes of these differing responses.   
Additionally, estrogen biosynthesis and aldosterone signaling are upregulated in 
the data set supporting the hypothesis of upregulation of the steroidogenesis pathway in 
atorvastatin exposure.  Furthermore, Figure 4.11 shows the effect of atorvastatin exposure 
on master regulators of steroid metabolism.  All master regulators in this data set were 
significantly upregulated relative to control, further supporting the hypothesis of 
upregulation of steroidogenesis concurrent with exposure to environmentally relevant 





Figure 4.11 Effect of atorvastatin exposure of master regulators of steroid metabolism 
with upregulated genes indicated in red. 
4.4 Conclusions 
The purpose of this assay was to evaluate potential endocrine disrupting effects of 
environmentally relevant concentrations of aqueous atorvastatin on tadpoles undergoing 
metamorphosis.  This experiment used molecular biomarkers previously validated by 
FETAX as measures of atorvastatin uptake and activity as well as introducing cyp19a1 as 
a biomarker for dysregulation of the steroidogenesis pathway.  Additionally, 
morphometric analysis of length, mass, and NF developmental stage were used as gross 
measurement of endocrine disruption.   
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Analysis of molecular biomarker expression levels indicated minimal cyp3a4 
mediated atorvastatin uptake.  This is unsurprising considering the non-traditional 
exposure routes in this assay design.  Cutaneous respiration is allowing for atorvastatin 
dosing despite lack of digestion.  This is allowing sufficient quantities of atorvastatin to 
enter the blood stream for drug activity as indicated by the significant upregulation of 
hmgcr.  Additionally, strong dose-dependent upregulation of cyp19a1 suggests 
upregulation of the steroidogenesis pathway and declining estrogen levels corresponding 
to atorvastatin dose as previously discussed.  This is further supported by RNA 
sequencing and bioinformatic analysis.  These data showed upregulation of the 
aldosterone signaling and estrogen biosynthesis pathway as well as blanket upregulation 
of the master regulatory network associated with steroid metabolism. 
Additionally, the RNAseq data also suggests significant generation of ROS and 
corresponding DNA damage repair.  This effect is confirmed in rats, but the opposite 
response is seen in human biomedical literature.  This differing response warrants further 
investigation and suggests a potential non-target effect not evident in humans. 
The morphometric analysis of growth and developmental parameters did not show 
overt alteration of development suggesting that low concentration transient exposures to 
aqueous atorvastatin do not affect amphibian metamorphosis rates.  However, the slight 
downward trend in NF developmental stage suggests that increased exposure 
concentrations or duration could magnify this effect and alter amphibian metamorphosis.  
This is particularly likely if tadpoles are exposed to atorvastatin from fertilization to NF 
47, which is where this test initiated.  Based on these data, environmentally relevant 
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concentrations of aqueous atorvastatin have an adverse effect of steroidogenesis by 
significantly dysregulating steroidogenesis. 
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CHAPTER V – ADULT ASSAY 
5.1 Introduction 
The purpose of the adult chronic assay was to evaluate potential endocrine 
disrupting effects of environmentally relevant concentrations of aqueous atorvastatin in 
X. laevis.  By sampling at the 4-week and 8-week time points, we add an additional 
temporal analysis for better resolution of effects timelines.  This assay was performed at 
the same environmentally relevant concentrations as the previous metamorphosis 
exposure and under the same flow-through conditions.  At termination, liver and 
digestive tissue, as well as blood, were collected and preserved for future analysis.  The 
liver and digestive samples were tested for the molecular biomarkers cyp3a4 (digestive), 
hmgcr (liver), and cyp19a1 (liver).  These biomarkers were used in the previous assays to 
evaluate atorvastatin uptake and activity, and dysregulation of steroidogenesis, 
respectively.  Those biomarkers were employed again in the adult assay for the same 
purposes.  In addition to the molecular biomarkers, the larger size of adults allows blood 
draw and isolation of large enough volumes of plasma to perform additional analysis of 
testosterone and estradiol levels as well as total plasma cholesterol concentrations.  These 
allow for additional investigation into potential endocrine disrupting effects of 
atorvastatin exposure on X. laevis. 
5.2 Endpoints and Protocols 
The endpoints for this assay were qPCR analysis of selected genes, hormone 
analysis of testosterone and estradiol, and plasma cholesterol quantitation.  As previously 
discussed, the molecular biomarkers employed for this assay have particular molecular 
signatures that are useful in evaluating and confirming atorvastatin dosing.  Statistical 
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analysis of all qPCR data was performed using a One-way ANOVA with Holm-Sidak 
pairwise comparisons.  When dosed with atorvastatin, the expected response is 
transcriptional upregulation of cyp3a4 and hmgcr in digestive and liver tissue, 
respectively.  Previously, atorvastatin exposure caused transcriptional upregulation of 
cyp19a1 and I anticipated a similar response in adults. 
With the additional ability to collect plasma from blood samples, additional 
assays were performed to measure testosterone, estradiol, and total cholesterol 
concentrations in plasma.  The testosterone and estradiol ELISA kits were previously 
validated for use in X. laevis using total cholesterol collected from whole body tissue of 
tadpoles from the FETAX experiment.  The Amplex Red Cholesterol Assay was 
validated from the manufacturer for use in X. laevis, and additional validation was 
deemed unnecessary.  Due to the extremely low concentrations of estradiol in males, and 
testosterone in females, it was not possible to test for opposing sex steroids.  Thus, males 
were evaluated for testosterone concentrations, and females were evaluated for estradiol 
concentrations.   
I anticipated a decline in testosterone and estradiol levels in both males and 
females, respectively, and large individual variability with respect to female estradiol 
concentrations.  Frogs were shipped on ice overnight and thawed upon receipt then 
acclimated to the exposure chamber for 7 days under clean flow-through conditions.  
While this is not a perfect solution, I hope that the cold snap served to “reset” the 




It was expected that total plasma cholesterol concentrations would decline when 
exposed to atorvastatin.  The aqueous atorvastatin concentrations tested were several 
orders of magnitude below the equivalent recommended therapeutic dose in humans.  
Additionally, the exposure route bypassed the digestive system as with the 
metamorphosis exposure.  Previously the transcriptional upregulation of cyp19a1 had a 
very significant response to a relatively minor dysregulation of cholesterol biosynthesis.  
Based on this observation, even the slightest alteration of total cholesterol concentrations 
would significantly alter steroidogenesis. 
5.3 Results 
5.3.1 Water Chemistry 
The adult chronic assay and metamorphosis assay were run in conjunction with 
one another, and as such, water quality was monitored continuously across both 
experiments to keep water chemistry parameters as well as atorvastatin concentrations 
consistent across both experiments.  Figure 5.1 shows recorded water quality parameters 
and standard deviation. No water quality parameters were significantly different across 

















































































Figure 5.1 Exposure tank water quality parameters by treatment. 
Similar to the metamorphosis experiment, water samples were collected at set-up, 
week-4, and termination (week-8).  These samples were shipped to Mississippi State 
Chemical Laboratory for validation of exposure concentrations using the previously 
described protocol.  Figure 5.2 shows atorvastatin concentrations in exposure water by 








































Figure 5.2 Atorvastatin concentration in exposure water by treatment. 
5.3.2 Molecular Analysis 
At termination, samples of liver and digestive tissue were collected, and flash 
frozen for later use in qPCR.  These samples were then extracted and analyzed following 
the previously described protocols.  The digestive tissue was analyzed for expression 
levels of cyp3a4, and the liver tissue was analyzed for hmgcr and cyp19a1.  Additionally, 
these data are further subdivided into 4-week and 8-week sampling points.  This sampling 
design allows for temporal analysis of exposure effects. 
Expression levels of cyp3a4 in digestive tissue is a biomarker of atorvastatin 
uptake as previously demonstrated.  These data show statistically significant upregulation 
relative to control of cyp3a4 at both the 4-week and the 8-week sampling point (Figure 
5.3) (p < 0.001, F = 110.96.5, df = 8). 
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Figure 5.3 Relative gene expression of cyp3a4 in digestive tissue of X. laevis exposed to 
atorvastatin. 
The 8-week sampling point shows a reduced upregulation significantly different from the 
4-week sampling point indicating temporal differences in expression levels relative to 
control.  These data are consistent with previous observations from the metamorphosis 
assay as well as the FETAX.  It is of note that this upregulation is much higher than 
previously seen in the metamorphosis exposure despite similar exposure routes of 
primarily cutaneous respiration supplemented with digestion.  One possible reason for 
differences in cyp3a4 expression magnitude is lipid differences in food.  Tadpoles and 
metamorphosing frogs are primarily filter feeders.  At this age stage, their diet consists 
primarily of powdered algae dissolved in water.  Adult frogs, however, were fed Xenopus 
Diet (Zeigler).  This scientifically formulated diet has more fat content, and given the 
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high lipophilicity of atorvastatin, it is unsurprising that we would see increased binding to 
food relative to algae contributing to increased upregulation of cyp3a4.  This statistically 
significant upregulation of cyp3a4 indicates that atorvastatin uptake is occurring in the 
adult frogs. 
Expression levels of hmgcr in liver tissue is a biomarker of atorvastatin activity.  
These data indicate statistically significant (p < 0.001 F = 76.074, df = 8), dose dependent 
upregulation of hmgcr at the 4-week time point, however, this effect is abolished over 
time (Figure 5.4).  This indicates strong and rapid return to baseline expression levels as 
the enzyme reaches saturation.  This threshold effect does not indicate reactivation of 
endogenous cholesterol production, rather it indicates the beginning of acclimation to 




Figure 5.4 Relative gene expression of hmgcr in liver tissue of X. laevis exposed to 
atorvastatin. 
Expression levels of cyp19a1 in liver tissue is a biomarker of steroidogenesis 
dysregulation.  Figure 5.5 shows cyp19a1 expression levels in adult X. laevis exposed to 
aqueous atorvastatin.  These data show statistically significant, dose dependent 
upregulation at the 4-week sampling point, with an even more pronounced effect at the 8-
week sampling point (p = 0.002 F = 22.84, df = 8).  This is indicative of rapid, significant 
dysregulation of steroidogenesis with the effect increasing over time and with dose.  As 
previously discussed, this response is associated with increase conversion of testosterone 
to estradiol consistent with declining estradiol levels. 
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Figure 5.5 Relative gene expression of cyp19a1 in liver tissue of X. laevis exposed to 
atorvastatin. 
In its entirety, this molecular fingerprint is consistent with previous data 
indicating uptake and activity of atorvastatin.  Despite the uptake and activity biomarkers 
indicating acclimation to atorvastatin dosing occurring around the 4-week time point, the 
upregulation of steroidogenesis persists and continues to increase by week 8.  This effect 
further highlights how a minor inhibition of cholesterol biosynthesis significantly 
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5.3.3 Hormone Analysis 
Samples collected at both the four- and eight-week time points were analyzed via 
ELISA using the previously described protocol.  Plasma samples were isolated from 
collected blood via centrifuge and were analyzed for testosterone concentration in males 
and estradiol concentration in females. 
 
Plasma Testosterone Concentration


















































Figure 5.6 Plasma testosterone concentrations relative to control in adult male X. laevis 
exposed to aqueous atorvastatin sampled at multiple time points. 
Figure 5.6 shows testosterone concentrations by treatment relative to control at 
both the four and eight-week sampling points.  At the four-week time point, testosterone 
concentrations were not significantly different from control (p = 0.01, F = 10.94, df = 8).  
At the eight-week time point, testosterone concentrations differed significantly from 
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control.  In the 0.7 ug L-1 treatment, testosterone concentrations were increased 
significantly relative to control and the high treatment.  Control frogs had a mean plasma 
testosterone concentration of 1.09±0.27 ng L-1(n=3) and the 0.7 ug L-1 atorvastatin 
treatment had a mean plasma testosterone concentration of 8.27±1.82 ng L-1(n=3).  This 
is a 658% increase in plasma testosterone concentrations at the lower atorvastatin 
treatment in the assay.  The higher 4.4 ug L-1 treatment was also significantly increased 
relative to control although not to the extreme that the lower treatment was increased.  
The mean plasma testosterone concentration in the higher treatment was 3.15±0.60 ng L-
1, an increase of 189% relative to control.  These data indicate that at 4 weeks, plasma 
testosterone concentrations were unaffected by atorvastatin, however, at the 8-week time 
point, elevated testosterone levels are evident with the greatest magnitude of change in 
the mid treatment.  This lag in testosterone production is unsurprising as males will have 
significant enough quantities Cyp19a1 to sustain testosterone conversion for a 
considerable amount of time before additional protein production is required.  This is 
likely resulting in an overcorrection in treated groups due to the previously seen increase 
in cyp19a1 expression over time.  While these data are not sufficient to predict a decline 
in estradiol levels, they are significant enough to indicate an endocrine disrupting effect 
in male frogs exposed to environmentally relevant concentration of aqueous atorvastatin. 
As previously discussed, the significant upregulation of cyp19a1 points to a 
potential alteration in plasma estradiol levels increasing in severity as atorvastatin dose 
increases. Plasma estradiol concentrations of adult females exposed to atorvastatin are 










































Figure 5.7 Plasma estradiol concentrations relative to control in adult female X. laevis 
exposed to aqueous atorvastatin sampled at multiple time points. 
A similar dose response to the male testosterone levels is present in the lower 0.7 ug L-1 
treatment.  Mean plasma estradiol concentrations were increase substantially at the four-
week time point.  Unlike the male testosterone levels, however, there is a significant 
decrease in circulating estradiol levels in the higher treatment at the 4-week time point 
with the decline continuing into the eight-week time point.  These data strongly correlate 
with the strong, dose dependent upregulation of cyp19a1 in the highest treatment and 
confirms predictions of dysregulation of steroidogenesis accompanied by a significant 
decline in circulating estradiol levels at 4.4 ug L-1 concentrations.  The 0.7 ug L-1 
treatment shows significantly increased plasma estradiol concentrations with the effect 
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declining with time.  While this is contradictory to expectations, it can be explained 
primarily by gender differences in the frogs.   
As discussed in the materials and methods, adult female X. laevis are twice the 
size of their male counterparts.  The males used in this assay were 50±1 g and the females 
used in this experiment were 100±1 g in mass.  This drastic mass difference will drive a 
different dose response relationship in males versus females when exposed to the same 
dose.  This affects two main dose response relationships.  As cutaneous respiration 
accounts, at least in part, for atorvastatin uptake, body mass to surface area ratio is of 
significance.  It is well known that as mass increases in an organism, the surface area to 
volume ratio decreases.  This is beneficial for uptake via cutaneous respiration as the 
larger female frogs will experience reduced uptake when compared to their male 
counterparts.   
Additionally, the increased mass of the female frogs means that they must receive 
a higher dose per organism to match the dose of their male counterparts.  The goal of this 
experiment was environmental relevance, as such, the aqueous dose administered was 
based on environmentally relevant concentrations rather than equivalent dosing by mass.  
This means that the dose received by the female frogs was lower than the dose received 
in the male frogs.  The threshold effect previously described in the hmgcr data indicate 
that at the lower concentrations, the larger females received a lower dose per body mass 
allowing compensation of endocrine disrupting effects.  In contrast, the threshold was 





5.3.4 Cholesterol Analysis 
In addition to sex steroid analysis, plasma cholesterol levels were also evaluated.  
The protocol for the Amplex Red cholesterol assay has been previously discussed.  
Simply put, this colorimetric assay is capable of determining free and bound cholesterol 
in plasma and was previously validated for use with X. leavis. 
Figure 5.8 shows plasma cholesterol concentrations in males exposed to aqueous 
atorvastatin for 60 days.  Plasma cholesterol concentrations were significantly reduced at 
both the four- and eight-week time-points (p < 0.001, F = 42.26, df = 8).  In general, the 
higher treatment saw a lesser reduction, however across all treatments and time points 
plasma cholesterol levels were significantly lower than control suggesting targeted effects 
of atorvastatin correlating with increased uptake and activity relative to control.  Based 
on these data, male frogs exposed to atorvastatin experience hypocholesterolemia relative 
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Figure 5.8 Plasma cholesterol concentrations relative to control in adult male X. laevis 
exposed to aqueous atorvastatin sampled at multiple time points. 
Plasma cholesterol concentrations for the females showed a very different effect.  
Figure 5.9 shows plasma cholesterol concentrations relative to control in adult female X. 
laevis exposed to aqueous atorvastatin (p < 0.001, F = 51.76, df = 8).  Only the lower 0.7 
ug L-1 treatment showed a reduction in plasma cholesterol and only at the 4-week time 
point.  Plasma cholesterol was reduced 24.5% from 1449.57±28.29 ug mL-1 to 
1093.32±20.70 ug mL-1 relative to control.  This reduction was completely abolished by 
the eight-week time point and showed an increase of 630% to 2876.17±99.00 ug mL-1.  
The higher 4.4 ug L-1 treatment showed increases of 35% at four weeks to 1962.9±28.36 
ug mL-1 and a 16% increase at eight weeks to 2047.58±84.50 ug mL-1 relative to controls.  
As previously discussed, it is possible that the larger mass of the female frogs contributed 
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to a lower overall dose received relative to body mass.  This dose may have been 
sufficiently low enough to fail to elicit target effects in the female frogs.  The cholesterol 
response from the females in this experiment may have been a byproduct of non-target 
effects which have been previously shown in this study to be quite dramatic despite 
relatively minor dysregulation of cholesterol biosynthesis. 
Plasma Cholesterol Concentrations by Treatment
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Figure 5.9 Plasma cholesterol concentrations relative to control in adult female X. laevis 
exposed to aqueous atorvastatin sampled at multiple time points. 
5.4 Conclusions 
The goal of the adult chronic assay was to evaluate potential endocrine disrupting 
effects of aqueous exposure to environmentally relevant concentrations of atorvastatin at 
multiple time points in adult males and female X. laevis.  The endpoints measured for this 
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assay were transcriptional regulation of cyp3a4, hmgcr, and cyp19a1 as well as 
measurement of plasma cholesterol, testosterone, and estradiol concentrations.   
The molecular signature in this assay confirmed atorvastatin uptake and activity 
by cyp3a4 and hmgcr transcriptional upregulation particularly at the 4-week time point.  
This effect diminished at the 8-week time point.  Despite this, cyp19a1 upregulation 
continued to increase through the 8-week time point indicating dysregulation of 
steroidogenesis and declining estradiol concentrations. 
Plasma testosterone and estradiol concentrations were evaluated to confirm non-
target effects of atorvastatin predicted by the upregulation of cyp19a1.  Testosterone 
concentrations in males were unchanged relative to control at the 4-week time point with 
elevated testosterone levels by week 8.  It is hypothesized that this increase is a byproduct 
of increased testosterone production consistent with general upregulation of 
steroidogenesis.  This hypothesis is further supported by the plasma estradiol 
concentrations measured in this experiment.  Plasma estradiol was elevated in the lower 
atorvastatin dose and significantly decreased in the higher treatment.  The differences in 
this response are hypothesized to be due primarily to the larger mass of female X. laevis 
contributing to a reduced dose per body mass.  It is believed that this reduced dose failed 
to achieve the threshold necessary to elicit non-target effects. 
Plasma cholesterol concentrations confirmed target effects in males with 
significant reduction in circulation cholesterol increasing over time.  However, the female 
cholesterol concentrations increased with atorvastatin dosing in all but the low treatment 
and only at the 4-week time point.  This effect further confirms the hypothesis that the 
larger mass of females allows them to withstand higher concentrations of atorvastatin 
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before target effects are apparent.  Taken into context with the previously discussed 
estradiol data, it appears that the threshold for eliciting non-target effects of reduced 
plasma estradiol is lower than the threshold to elicit target effects of reduction of 
circulating cholesterol.   
The data from this assay indicate environmentally relevant concentrations of 
aqueous atorvastatin have an adverse effect of steroidogenesis by significantly 
upregulating conversion of testosterone to estradiol in the face of declining estradiol 
levels.  This effect is more pronounced in males primarily due to their smaller size.  
Female X. laevis demonstrate a greater tolerance for aqueous atorvastatin with target 
effects not apparent in this assay, and non-target effects appearing only in the 4.4 ug L-1 
treatment.  This supports the hypothesis the aqueous atorvastatin has endocrine disrupting 
potential at environmentally relevant concentrations. 
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CHAPTER VI – CONCLUSION 
This research investigated the non-target effects of exposure to environmentally 
relevant concentrations of aqueous atorvastatin.  Previous research has shown that 
wastewater treatment plants do not sufficiently remove atorvastatin from wastewater 
during the treatment process(Halling-Sørensen et al., 1998; Jelic et al., 2011; Lee et al., 
2009; Ort et al., 2010) resulting in discharge of atorvastatin in wastewater effluent at or 
below 2ug L-1(Jelic et al., 2011; Lee et al., 2009).  I hypothesize that these low 
concentrations of aqueous atorvastatin are sufficient to elicit the non-target effects of 
alteration of circulating testosterone and estradiol as a consequence of inhibition of 
endogenous production of cholesterol potentially resulting in alteration of growth, 
development, and sexual differentiation in amphibians localized near wastewater effluent 
sites.   
This research sought to investigate these non-target effects using traditional 
aquatic toxicology assays combined with modern molecular biology techniques to 
identify and report regulatory alteration of physiological pathways in a model amphibian, 
Xenopus laevis.  This was investigated via three primary assays.  First, a modified 
FETAX assay was employed to evaluate the target and non-target effects of atorvastatin 
exposure at high concentrations on developing tadpoles.  Second, the molecular 
fingerprint developed from the FETAX assay was used to verify exposure effects of 
chronic exposure to aqueous atorvastatin at environmentally relevant concentrations on 
metamorphosing tadpoles.  Finally, a chronic adult exposure at environmentally relevant 
concentrations was used to determine the non-target effects of atorvastatin exposure on 
circulating testosterone and estradiol concentrations in amphibians. 
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The results of the FETAX validated biomarkers of uptake, activity and efficacy of 
atorvastatin in X. laevis.  These biomarkers were upregulation of cyp3a4, and hmgr for 
uptake and activity respectively, and efficacy was validated by significant reduction in 
total cholesterol.  The directionality of this dysregulation was consistent with the 
response of the same biomarkers in humans administered atorvastatin as treatment for 
hypercholesterolemia.  These data confirm that atorvastatin has the potential to elicit the 
same targeted responses to atorvastatin exposure as humans. 
Investigation into non-target effects of atorvastatin at environmentally relevant 
concentrations began with the chronic metamorphosis assay.  The results of this assay 
indicated significant upregulation of biomarkers related to inhibition of cholesterol 
biosynthesis and showed dose-dependent upregulation of cyp19a1 suggesting a molecular 
response to declining estrogen concentrations.  This non-target effect was confirmed via 
total RNA sequencing, and showed significant upregulation of master regulators 
associated with steroid metabolism.  Furthermore, RNA sequencing confirmed activation 
of the canonical pathways for estrogen biosynthesis and aldosterone signaling.  
Combined, these data indicate that exposure to aqueous atorvastatin alters steroidogenesis 
and results in declining sex steroid concentrations consistent with findings in zebrafish 
exposed to atorvastatin(Al-Habsi et al., 2015).   
Morphometric analysis of length, mass and developmental stage did not indicate 
overt alteration of growth or development suggesting that transient exposure to 
environmentally relevant concentrations of atorvastatin was not sufficient to alter growth 
and development, however the data do suggest that longer term exposures or higher 
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concentrations may still alter rates of metamorphosis highlighting a need for further study 
into complete life cycle exposures.   
Additionally, RNA sequencing confirmed generation of ROS and concurrent 
DNA damage repair consistent with findings from other researchers (Bouitbir et al., 
2011, 2016).  This response is contradictory to findings in the medical community 
suggesting that atorvastatin serves to ameliorate the effects of ROS generation and 
oxidative stress(Briones et al., 2009; Ceriello et al., 2005; Sugiyama et al., 2005).  These 
contradictory findings suggest a potential difference in the response of humans versus 
amphibians exposed to atorvastatin and warrant future investigation into these 
differences. 
Circulating cholesterol concentrations in males and females exposed to 
atorvastatin are indicative of targeted effects of atorvastatin exposure.  Male X. laevis 
showed a dose-dependent and time dependent reduction in circulating cholesterol 
indicating the targeted effect of atorvastatin exposure is evident in in the smaller males 
even at the low environmentally relevant concentrations.  Cholesterol concentrations in 
females show a general increase in cholesterol concentrations suggesting that the larger 
body mass of females provide some degree of protection from targeted effects of 
atorvastatin exposure at environmentally relevant concentrations.  These sexual 
differences in body mass are also evident in testosterone and estradiol concentrations as 
well. 
The adult chronic assay further confirms findings from the metamorphosis assay 
with relation to dysregulation of steroidogenesis.  These data show strong, dose-
dependent upregulation of steroidogenesis and declining estradiol concentrations in adult 
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female X. laevis at 4.4 ug L-1.  While the lower 0.7 ug L-1 did not show a decrease in 
circulating estradiol concentration, this is believed to be an artifact of mass differences in 
adult males and females as female X. laevis are significantly larger than their male 
counterpart.  This may result in female X. laevis receiving a lower dose per body mass 
resulting in decreased non-target effects at lower concentrations.  Testosterone 
concentrations in males were unaffected at 4-weeks, with elevated testosterone 
concentrations at 8-weeks.  These findings suggest that testosterone concentrations are 
unaffected in the short term and are unsurprising given the increased capacity for 
testosterone production in males of any species.  Relative to control, adult males and 
females show alteration of hormone level inconsistent with predictions suggesting that 
dysregulation of steroidogenesis is occurring in frogs exposed to atorvastatin in an 
unpredictable manner.  The directionality of this dysregulation is inconsistent with 
predictions indicating the need for further research into the exact nature of this 
dysregulation.   
This research provides further insight into the potentially harmful non-target 
effects of relatively low concentrations of aqueous atorvastatin discharged in bodies of 
water inhabited by amphibians.  The data indicate significant dose-dependent 
upregulation of steroidogenesis as confirmed by both qPCR and total RNA sequencing.  
While these data do not indicate overt morphological alteration of metamorphosis in 
these short exposures, on a molecular level, the early indicators of endocrine disruption 
are evident, and this conclusion is further supported by alteration of testosterone and 
estradiol concentration in adults.  While it was not possible to measure testosterone and 
estradiol concentrations in metamorphosing tadpoles, the increased sensitivity of earlier 
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life stages to aquatic toxins combined with the molecular signature indicating 
upregulation of steroidogenesis suggest that alteration of sex steroid levels is occurring 
and has the potential to significantly alter sex ratios in populations localized around 
wastewater effluent sites.  Based on these data, I fail to reject the hypothesis that 
environmentally relevant concentrations of aqueous atorvastatin are sufficient to elicit the 
non-target effects of alteration of circulating testosterone and estradiol as a consequence 
of inhibition of endogenous production of cholesterol potentially resulting in alteration of 
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